EUVIMEDEUVIMED entdecken
Crossref

Class III Obesity as a Presenting Syndrome in Prolactinoma Patients: Insights Into Obesity and Metabolic Dysfunction in This Unique Group

Lukas Andereggen iD, Christoph Schmid, Michael Brändle, Emanuel Christ

Clinical Obesity · 2026

DOI: 10.1111/cob.70067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Obesity, 2026. Verfasst von Lukas Andereggen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland. Hauptthemen laut MEDLINE: Obesity, Obesity, Morbid, Pituitary Neoplasms, Prolactinoma. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The occurrence of patients with lactotroph adenoma presenting with class III obesity is extremely rare. This study reports long‐term outcomes of such patients treated with transsphenoidal surgery (TSS) or dopamine agonists (DAs) and integrates findings with existing literature to explore prolactin's (PRL) role in obesity pathophysiology. We analysed BMI and metabolic changes and compared findings with published case series. Four patients presented with class III obesity (BMI range, 40.0–43.1 kg/m 2 ). The diagnostic work‐up revealed hyperprolactinemia (PRL range, 56.1–4389 μg/L) and hypogonadism in all patients, with sellar MRI indicating a macroadenoma in all but one patient. Over a median follow‐up of 31 months (range 24–144), both TSS ( n = 2) and DAs ( n = 2) effectively controlled hyperprolactinemia and hypogonadism. BMI changes (ΔBMI/year) were −1.4 ± 1.8 kg/m 2 /year (TSS) and −3.9 ± 3.4 kg/m 2 /year (DAs), with non‐significant metabolic improvements. Analysis of 22 additional cases revealed similar trends. Higher baseline BMI and macroprolactinoma were risk factors for persistent obesity. Early PRL screening in patients with class III obesity, weight loss interventions and long‐term hyperprolactinemia management are essential. Both TSS and DAs provide metabolic benefits, highlighting the need for a multidisciplinary approach in diagnosing and managing lactotroph adenomas with obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityObesity, MorbidPituitary NeoplasmsProlactinomaAdultFemaleHumansMaleMiddle AgedBody Mass IndexDopamine AgonistsHyperprolactinemiaHypogonadismProlactinRisk FactorsAdolescentYoung Adult

Stichwörter der Autor:innen

dopamine agonistmetabolic responseobesityprolactinomasurgery

Substanzen

Dopamine AgonistsProlactin

Autor:innen und Institutionen

  • Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland.
  • Faculty of Medicine, University of Bern, Bern, Switzerland.
  • Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • Division of Endocrinology and Diabetes, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
  • Department of Endocrinology, Diabetology and Metabolism, University Hospital of Basel, Basel, Switzerland.
  • Department of Clinical Research, University of Basel, Basel, Switzerland.

ORCID-Profile: Lukas Andereggen

Zitieren

APA

Andereggen, L., Schmid, C., Brändle, M., & Christ, E. (2026). Class III Obesity as a Presenting Syndrome in Prolactinoma Patients: Insights Into Obesity and Metabolic Dysfunction in This Unique Group. Clinical Obesity. https://doi.org/10.1111/cob.70067

Vancouver

Andereggen L, Schmid C, Brändle M, Christ E. Class III Obesity as a Presenting Syndrome in Prolactinoma Patients: Insights Into Obesity and Metabolic Dysfunction in This Unique Group. Clinical Obesity. 2026. doi:10.1111/cob.70067

BibTeX
@article{Andereggen2026,
  author = {Andereggen, Lukas and Schmid, Christoph and Brändle, Michael and Christ, Emanuel},
  title = {Class III Obesity as a Presenting Syndrome in Prolactinoma Patients: Insights Into Obesity and Metabolic Dysfunction in This Unique Group},
  journal = {Clinical Obesity},
  year = {2026},
  doi = {10.1111/cob.70067}
}
Kostenlos starten →